Abstract
Six commercial tests (Albicans ID, bioMérieux, France; CandiSelect, Sanofi Diagnostics Pasteur, France; CHROMagar Candida, Becton Dickinson, USA; Fluoroplate Candida, Merck, Germany; Fongiscreen 4H, Sanofi Diagnostics Pasteur; and Murex Candida albicans, Murex Diagnostics, USA) and the germ-tube test for presumptive identification of Candida albicans were evaluated using clinical isolates of Candida albicans (n = 350) and of non-albicans yeasts (n = 135). Sensitivities and specificities of all tests regarding the identification of Candida albicans were greater than 97%. The two tests that also allow presumptive identification of some non-albicans yeasts (CHROMagar Candida and Fongiscreen 4H) did not identify all isolates of Candida glabrata and Candida tropicalis. In addition, CHROMagar Candida identified as Candida glabrata some isolates belonging to different species of non-albicans yeasts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
